Skip to content
Screener

Revolution Medicines, Inc. RVMD Q2 2025 earnings

Reported August 6, 2025 · After market close

Revenue-
EPS-$1.31Miss by $0.37
EPS estimate-$0.94

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$13.4M
EPS estimate-$2.44

Financials

Q2 2025

Income statement

See full
Revenue-—
Operating income-$264.7M-69.0%
Net income-$247.8M-86.0%
EPS (diluted)-$1.31-61.7%

Balance sheet

See full
Cash & equivalents$402.4M+46.0%
Total debt$132.8M+51.9%
Total equity$1.9B+15.2%
Total assets$2.4B+34.3%

Cash flow

See full
Operating cash flow-$221.8M-73.0%
CapEx$7.5M+211%
Free cash flow-$229.2M-75.5%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$7.46B+16.3%
Enterprise value$7.19B+15.5%

Returns & leverage

See full
Return on equity-46.6%+7.9pp
Debt / equity0.1×0.0×
Current ratio11.8×-3.6×

FAQ

When did Revolution Medicines, Inc. report Q2 2025 earnings?
Revolution Medicines, Inc. (RVMD) reported Q2 2025 earnings on August 6, 2025 after market close.
What were Revolution Medicines, Inc.'s Q2 2025 revenue and EPS?
Revolution Medicines, Inc. reported revenue of - and eps of $-1.31 for Q2 2025.
Did Revolution Medicines, Inc. beat estimates in Q2 2025?
EPS missed the consensus estimate of $-0.94 by $0.37.
How did Revolution Medicines, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 61.7% from $-0.81.
Where can I find Revolution Medicines, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-103983) and the 10-Q periodic report (0000950170-25-104022) directly on SEC EDGAR. The filing index links above go to sec.gov.